Hot Features
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and sign... Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.3054 | -34.55532926 | 0.8838 | 0.924 | 0.43 | 1504746 | 0.56442614 | CS |
| 4 | -0.3731 | -39.2117708881 | 0.9515 | 1.0199 | 0.43 | 573136 | 0.66495557 | CS |
| 12 | -0.7316 | -55.8473282443 | 1.31 | 1.335 | 0.43 | 498072 | 0.81727257 | CS |
| 26 | -1.0216 | -63.85 | 1.6 | 2.07 | 0.43 | 602889 | 1.29514729 | CS |
| 52 | -5.3816 | -90.2953020134 | 5.96 | 7.19 | 0.43 | 808616 | 1.95587152 | CS |
| 156 | -1.0216 | -63.85 | 1.6 | 31.01 | 0.4 | 472775 | 4.47921189 | CS |
| 260 | -13.4816 | -95.8862019915 | 14.06 | 31.01 | 0.3862 | 693584 | 5.59110757 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.